Implementation and Operational Research: Integrated Pre-Antiretroviral Therapy Screening and Treatment for Tuberculosis and Cryptococcal Antigenemia : JAIDS Journal of Acquired Immune Deficiency Syndromes

Secondary Logo

Journal Logo

Advanced Search
Clinical Science

Implementation and Operational Research

Integrated Pre-Antiretroviral Therapy Screening and Treatment for Tuberculosis and Cryptococcal Antigenemia

Pac, Lincoln MD*; Horwitz, Mara Murray MD*; Namutebi, Anne Marion MBChB, MMed*; Auerbach, Brandon J. MD*; Semeere, Aggrey MBChB, MMed*; Namulema, Teddy MBChB, MMed*; Schwarz, Miriam MD*; Bbosa, Robert MS*; Muruta, Allan MBChB, MMed†; Meya, David B. MBChB, MMed*,‡,§; Manabe, Yukari C. MD*,‖

Author Information

*Research Department, Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda;

†Ministry of Health, Uganda;

‡Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda;

§Department of Medicine, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota, Minneapolis, MN; and

‖Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD.

Correspondence to: Yukari C. Manabe, MD, 1830 E Monument Street, Rm 443, Baltimore, MD 21205, (e-mail: [email protected]).

This work is supported by the United States National Institutes of Health Office of the Director, Fogarty International Center, Office of AIDS Research, National Cancer Center, National Eye Institute, National Heart, Blood, and Lung Institute, National Institute of Dental & Craniofacial Research, National Institute On Drug Abuse, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases Health, and NIH Office of Women's Health and Research through the International Clinical Research Scholars and Fellows Program at Vanderbilt University (R24 TW007988). Funding for this study is also provided by a Pfizer Investigator-Initiated Research Grant (Y.C.M., D.B.M.). Diflucan (fluconazole) was kindly donated by Pfizer. Y.C.M. also receives salary support from the Fogarty International Center, NIH (1R25TW009340, R24TW008861, R24TW007988, and D43TW009771) and Johns Hopkins University Center for AIDS Research (Grant Number 1P30AI094189 from the National Institute of Allergy And Infectious Diseases).

L.P., M.H.H., B.J.A., A.S., M.S., A.M.N., and T.N. were all Fogarty Scholars. The remaining authors have no conflicts of interest to disclose.

L.P. and M.H.H. contributed equally to this article. M.S., T.N., and Y.C.M. conceived the study, designed the study, and wrote the study protocol. B.J.A. and A.S. edited the study protocol and coordinated the study. L.P., A.M.N., M.H.M., and R.B. coordinated and completed the study. D.B.M. contributed to the study design in the area of cryptococcal disease. A.M. contributed to the conception of the study at Kiboga District Hospital. All authors contributed to the writing and editing of this manuscript. All authors read and approved the final manuscript.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).

Received August 04, 2014

Accepted December 03, 2014

JAIDS Journal of Acquired Immune Deficiency Syndromes 68(5):p e69-e76, April 15, 2015. | DOI: 10.1097/QAI.0000000000000527

Abstract

Objective: 

To demonstrate the feasibility of integrated screening for cryptococcal antigenemia and tuberculosis (TB) before antiretroviral therapy (ART) initiation and to assess disease specific and all-cause mortality in the first 6 months of follow-up.

Methods: 

We enrolled a cohort of HIV-infected, ART-naive adults with CD4 counts ≤250 cells per microliter in rural Uganda who were followed for 6 months after ART initiation. All subjects underwent screening for TB; those with CD4 ≤100 cells per microliter also had cryptococcal antigen (CrAg) screening. For those who screened positive, standard treatment for TB or preemptive treatment for cryptococcal infection was initiated, followed by ART 2 weeks later.

Results: 

Of 540 participants enrolled, pre-ART screening detected 10.6% (57/540) with prevalent TB and 6.8% (12/177 with CD4 count ≤100 cells/μL) with positive serum CrAg. After ART initiation, 13 (2.4%) patients were diagnosed with TB and 1 patient developed cryptococcal meningitis. Overall 7.2% of participants died (incidence rate 15.6 per 100 person-years at risk). Death rates were significantly higher among subjects with TB and cryptococcal antigenemia compared with subjects without these diagnoses. In multivariate analysis, significant risk factors for mortality were male sex, baseline anemia of hemoglobin ≤10 mg/dL, wasting defined as body mass index ≤15.5 kg/m2, and opportunistic infections (TB, positive serum CrAg).

Conclusions: 

Pre-ART screening for opportunistic infections detects many prevalent cases of TB and cryptococcal infection. However, severely immunosuppressed and symptomatic HIV patients continue to experience high mortality after ART initiation.

INTRODUCTION

Efforts to address the high burden of HIV disease in sub-Saharan Africa (SSA) have led to a rapid increase in the number of patients receiving antiretroviral therapy (ART). With 4.2 million fewer HIV-related deaths in low- and middle-income countries between 2002 and 2012 and 9 million sub-Saharan Africans projected to be receiving ART by the end of 2014, the expansion in ART access has been dramatic and life-saving.1,2 However, in a meta-analysis of sub-Saharan Africans initiating ART, 17% (range, 11%–24%) died within the first year, largely because of opportunistic pathogens, such as Mycobacterium tuberculosis and Cryptococcus neoformans.3 Mortality in the first year on ART was as high as 40%, with the majority of deaths occurring in the first 3 months after ART initiation.3–5 Patients with the lowest CD4 T-cell counts have the highest mortality risk,5–11 and despite expanded voluntary HIV counseling and testing efforts, many patients still present with advanced immunosuppression.12–15

C. neoformans is a ubiquitous soil fungus that causes an estimated 720,000 cases of cryptococcal meningitis (CM) annually in SSA.16 In HIV-infected Africans, CM is responsible for up to 20% of deaths in the first year on ART.4 Serum cryptococcal antigen (CrAg) positivity is an independent predictor of mortality17–21 and is prevalent in 2%–21% of HIV-infected patients with CD4 count ≤100 cells per microliter.17–19,22–25 CrAg screening and preemptive fluconazole treatment has been shown to reduce CM-related mortality and is cost effective.24,26

There is a significant burden of undiagnosed TB in populations with a high prevalence of HIV.27–30 Prospective cohort studies in South Africa have demonstrated that 17%–19% of HIV-infected ART-eligible patients have positive sputum cultures for TB.31–34 It is also known that patients with active TB at the time of ART initiation have a high mortality rate in the first few years after starting ART.35–37 This suggests that more intensive pre-ART TB screening and treatment may avert mortality.

As national programs work toward the United Nations goal of 15 million persons on ART by 2015,1,38 the ability of ART programs to effectively diagnose and treat opportunistic infections (OIs) in the early ART period will be essential to reduce mortality. In rural areas, ART programs face the additional challenges of limited diagnostic and treatment services and widely dispersed patient populations.39,40 Although WHO guidelines recommend screening for TB in HIV patients,41 few studies have assessed the operational performance of TB diagnostic tests in rural populations. Therefore, we sought to describe the performance of integrated OI screening in a cohort of HIV-positive, ART-naive, rural Ugandans initiating ART in the second phase of the US President's Emergency Plan for AIDS Relief.

METHODS

Study Setting

We recruited patients at the Kiboga District Hospital HIV clinic, a rural government hospital 130 km northwest of Kampala, Uganda, which serves a multidistrict population of more than 300,000.42 In a 2011 Ugandan serosurvey, adult HIV prevalence in the region was 11.1% for women and 8.2% for men.43 First-line ART comprised either zidovudine (AZT) or tenofovir (TDF), lamivudine (3 TC), and either nevirapine (NVP) or efavirenz (EFV). Cotrimoxazole prophylaxis was initiated at the time of HIV diagnosis.

Study Design and Participants

Between September 23, 2010 and November 19, 2012, we prospectively enrolled HIV-positive ART-eligible (CD4+ T-cell count ≤ 250 cells/μL), and ART-naive adults ≥18 years of age after informed consent. Participants with alanine aminotransferase or aspartate aminotransferase > 5 times the upper limit of normal or creatinine clearance <25 mL/min were excluded from the study due to increased risk of medication-related adverse events. Those already receiving treatment for TB or cryptococcal disease were also excluded.

Screening and Treatment for OIs

Prior to ART initiation, participants with CD4 counts ≤100 cells per microliter were screened for cryptococcal infection using a latex agglutination assay for serum cryptococcal antigen (CrAg) (Immuno-Mycologics, Norman, OK) and clinical evaluation for signs and symptoms of CM.44 Serum CrAg-positive subjects were treated with a fungicidal dose of oral fluconazole (Diflucan, Pfizer), 800 mg daily for 4 weeks. If clinically stable after 2 weeks of treatment, these patients then began ART. Participants diagnosed with CM at screening were referred to Mulago National Referral Hospital for amphotericin treatment.

All participants underwent clinical and laboratory screening for TB, including: (1) 4 intensified case finding (ICF) screening questions developed from the WHO STOP-TB guidelines (current cough, fever, weight loss, or night sweats),41 (2) Ziehl-Neelsen staining and/or fluorescence microscopy for acid-fast bacilli (AFB) on 2 sputum smears, and (3) sputum culture on the first specimen. Participants unable to expectorate sputum underwent sputum induction with hypertonic saline. TB sputum samples were packaged with refrigerant and sent by courier to the Mycobacteriology laboratory (BSL-3) at Makerere University in Kampala, Uganda for TB culture analysis. Inoculated Mycobacterial Growth Indicator Tubes (MGIT) and Lowenstein-Jensen (LJ) media were incubated at 37°C and monitored for growth for up to 6 and 8 weeks, respectively, as previously described.45 TB status was defined using WHO criteria.46 Smear-positive TB was defined as one or more AFB-positive sputum samples. Smear-negative TB was defined as 2 AFB-negative sputum samples and evidence of pulmonary disease on chest radiograph and/or a positive sputum culture. Extrapulmonary TB (EPTB) was defined46 as one culture- or smear-positive specimen from an extrapulmonary site or strong clinical evidence of extrapulmonary disease (on lymph node aspirate, lymph node biopsy, and/or abdominal ultrasound), followed by a decision to begin full treatment. TB treatment was comprised of a 2-month induction phase with isoniazid, rifampin, pyrazinamide, and ethambutol (RHZE), followed by a 6-month continuation phase with isoniazid and ethambutol (EH).47 ART was initiated after 2 weeks of TB treatment.

Follow-up and Outcomes

We followed individuals for 6 months after ART initiation for the primary study outcomes of death and occurrence of major OIs (TB or CM). Censoring occurred upon one of the following events: death, transfer to another clinic, withdrawal from the study, loss to follow-up, administrative closure, or completion of 6 months of follow-up. Cause of death was determined by review of laboratory and clinical information for patients who died in the hospital. When death occurred at home, verbal autopsy questions were administered to family members of the deceased by a trained study assistant. A panel of at least 3 physicians reviewed all deaths and adjudicated the most likely cause of death. Participants were deemed lost to follow-up when they had missed an appointment for 4 weeks and could not be contacted or traced by the outreach team.

Data Collection

We collected data through interviews about demographics, past history of HIV disease, and clinical complaints, physical examination, and laboratory measurements. Participants were seen at enrollment, at 2 weeks, and then monthly for 6 months. Laboratory measurements included CD4+ T-lymphocyte (CD4) count (BD Facs Count; Becton Dickinson, San Jose, CA), complete blood count (Celltac E MEK-7222; Nihon Kohden, Tokyo, Japan); alanine aminotransferase, aspartate aminotransferase, total bilirubin (Flexor Junior; Vital Scientific, Dieren, the Netherlands), and serum creatinine (Cobas Integra 400 plus; Roche, Basel, Switzerland). Data were recorded on standardized clinical research forms at the study site and transmitted through the DataFax system to a secure server at the National Institutes of Health in Bethesda, MD.

Statistical Analysis

We used the Student's t-test to compare means of continuous variables. We used the χ2 test to compare proportions of dichotomous and polytomous data. Kaplan–Meier survival curves and stratified log-rank test were used to describe mortality per 100 person-years at risk (PYAR) in the first 6 months on ART. Finally, using the Cox proportional hazards regression, we evaluated risk factors for death, both in the entire cohort and the subset of participants with CD4 count ≤100 cells per microliter. Covariates for inclusion in the multivariate regression model were considered based on an unadjusted association with mortality (P < 0.25) and other previously published risk factors. A P value <0.05 was considered significant, and all reported P values were two-sided. Analyses were carried out using STATA (Version 11; StataCorp, College Station, TX).

Ethical Considerations

Informed consent discussions were conducted in the participant's primary language, either English or Luganda, and written consent forms were signed. For subjects with limited literacy, a witness not associated with the study was present to ensure full understanding. The study was approved by the relevant institutional review boards in Uganda (#HS740) and the Johns Hopkins University.

RESULTS

Patient Characteristics

Five hundred forty participants were enrolled between September 2010 and November 2012, and follow-up was completed in May 2013 (Fig. 1). Sixty percent (324/540) of the participants were female. At enrollment, median age was 36 years (interquartile range [IQR], 30–44 years), median CD4 count 155 cells per microliter (IQR, 72–206 cells/μL), mean hemoglobin (Hb) 11.7 g/dL (SD, 2.2 g/dL), and mean body mass index (BMI) 20.6 kg/m2 (SD, 3.4 kg/m2) (Table 1). Over a median follow-up period of 6.1 months (IQR, 5.7–6.3 months), 535 (99.1%) initiated ART and 22 (4.1%) were lost to follow-up.

F1-10
FIGURE 1:
Flow of study participants.
T1-10
TABLE 1:
Demographic Characteristics of the Cohort by 6-Month Study Outcome

CrAg Screening

Among 179 subjects with baseline CD4 count ≤ 100 cells per microliter, 177 (97.9%) were screened for serum CrAg. Pre-ART screening detected 12/177 (6.8%) cases of cryptococcal antigenemia. Of these, 1 who had symptoms of CM was diagnosed with CM with CrAg-positive cerebrospinal fluid (CSF) and was referred for treatment. Of the 11 who were asymptomatic, 9 underwent lumbar puncture (2 declined) and were CrAg-negative in CSF. All 11 were treated preemptively with high-dose fluconazole, reported perfect adherence, had no adverse events related to the treatment, and did not develop CM during follow-up. One subject (baseline CD4 count, 16 cells/μL) screened negative at enrollment, but after 2 weeks on ART developed symptoms of CM, was found to have CrAg-positive serum and CSF and subsequently died during treatment for CM.

Tuberculosis Screening

All 540 participants were evaluated for TB in pre-ART screening and follow-up visits. In total, 72 (13.3%) were diagnosed with TB. Of these, pre-ART screening detected 79.2% (57/72). Two additional patients were lost to follow-up and diagnosed posthumously with pre-ART TB (Table 2). Follow-up after ART initiation detected 13 additional cases of which 69.2% were extrapulmonary infections (see Figure S1, Supplemental Digital Content, https://links.lww.com/QAI/A626).

T2-10
TABLE 2:
Prevalent and Incident Tuberculosis

Of the participants whose first sputum smear was interpretable (513/540, 95.0%), 2.3% (12/513) were smear-positive. Four hundred participants who were smear-negative produced a second sputum sample (74.1% of those enrolled), of which 1.5% (6/400) were positive. Overall, one quarter (18/72) of all TB cases were smear-positive, and every smear-positive case presented with at least 1 symptom (94.4% cough, 94.4% weight loss, 55.6% night sweats, 50.0% fever, and 0% hemoptysis) on the ICF questionnaire.

Sputum cultures were performed in 64.3% (347/540) and not contaminated in 63.5% (343/540) of the participants enrolled (Table 2). Sputum cultures were positive in 51.0% (25/49) of patients who were clinically diagnosed with TB and started treatment; 71.4% (10/14) of smear-positive, 60.9% (14/23) of smear-negative, and 8.3% (1/12) of extrapulmonary TB cases. As with smear-positive cases, all patients with positive TB cultures were symptomatic.

Extrapulmonary cases were diagnosed by lymph node aspirate or biopsy showing AFBs (8%, 2/25), chest radiograph with evidence of pleural effusion (32%, 8/25), abdominal ultrasound showing lymphadenopathy (20%, 5/25), or clinical impression leading to decision to begin anti-TB treatment (40%, 10/25). Locations of extrapulmonary TB were pleural (32%, 8/25), lymph nodes (24%, 6/25), and disseminated (44%, 11/25).

Comparing patients with and without TB who screened positive on ICF symptoms, we found that weight loss (97.2% vs. 58.8%, P < 0.001), current fever (66.7% vs. 17.3%, P < 0.001), night sweats (63.9% vs. 20.1%, P < 0.001), and hemoptysis (9.7% vs. 2.6%, P = 0.002) were significantly more likely to occur in patients diagnosed with TB. The presence of cough was not significantly different between those with and without TB (79.2% and 78.4%, respectively, P = 0.89). Sensitivity and specificity of various screening tests are listed in Table S1 (see Supplemental Digital Content, https://links.lww.com/QAI/A626).

Mortality

There were 39 deaths in this cohort (7.2%) during 6.5 months of follow-up, 1 before ART initiation and 38 on ART, occurring at a rate of 15.6 (95% CI: 11.4 to 21.3) deaths/100 PYAR overall. Mortality after ART initiation markedly decreased in the second 3 months of follow-up; only 3 deaths occurred in this period compared with 36 deaths in the first 3 months (99.4% vs. 93.3% survival). Causes of death were 9 TB-related (23.1%), 1 possible CM immune reconstitution inflammatory syndrome (2.6%), 7 KS-related (17.9%), 12 acute infections (30.8%), and 10 other (25.6%). Death rates in the 6-month post-ART follow-up period were significantly higher among subjects with TB compared with those without TB (41.2 deaths/100 PYAR; 95% CI: 22.8 to 74.5 vs. 9.55 deaths/100 PYAR; 95% CI: 6.2 to 14.6; P < 0.001) and higher among those with a CD4 count ≤ 100 cells per microliter who screened positive for serum CrAg compared with those who were CrAg-negative (114.9/100 PYAR; 95% CI: 43.1 to 306.3 vs. 25.1/100 PYAR; 95% CI: 15.8 to 39.9; P = 0.018) (Fig. 2). During the study period, 25% (3/12) of the baseline CrAg-positive participants and 20.3% (12/59) of the participants diagnosed with TB at pre-ART screening died.

F2-10
FIGURE 2:
Post-ART mortality outcomes stratified by OI and CD4. Kaplan–Meier survival plot showing significantly decreased survival for participants with TB and those with CD4 count ≤100 cells per microliter with positive serum CrAg, compared with the entire cohort, patients without TB or serum CrAg, and patients with CD4 count ≤100 cells per microliter and negative serum CrAg.

In multivariate analysis, significant risk factors for mortality were male sex (HR, 2.36; 95% CI: 1.13 to 4.93; P = 0.022), baseline Hb ≤10 mg/dL (HR, 12.84; 95% CI: 2.15 to 76.71; P = 0.005), BMI ≤15.5 kg/m2 (HR, 3.99; 95% CI: 1.44 to 11.00; P = 0.008), and TB infection (HR, 3.39; 95% CI: 1.54 to 7.48; P = 0.002) (Table 3). BMI 15.6–18.5 kg/m2 was associated with mortality but did not reach statistical significance (HR, 2.22; 95% CI: 0.98 to 5.02; P = 0.056). In multivariate analysis of participants with CD4 <100 cells per microliter, after serum CrAg screening results were added to the model, positive serum CrAg and BMI ≤15.5 kg/m2 were the only significant risk factors (HR, 4.50; 95% CI: 1.18 to 17.16; P = 0.028 and HR, 5.69; 95% CI: 1.44 to 22.48; P = 0.013, respectively), while TB infection trended toward significance (HR, 2.77; 95% CI: 0.97 to 7.94; P = 0.057).

T3-10
TABLE 3:
Multivariate Logistic Regression of Factors Associated With Mortality

DISCUSSION

In our cohort, serum CrAg screening and preemptive treatment with 4 weeks of high-dose fluconazole resulted in only 1 subject being diagnosed with CM in the first 6 months of ART treatment. This rate (2.6%) is significantly lower than the 12%–20% of deaths reported in other sub-Saharan cohorts4,5,10 and corroborates the modeled benefits of CrAg screening and preemptive fluconazole treatment.24,26

Despite a marked reduction in CM deaths, one quarter of subjects with positive serum CrAg at baseline died during the study period—a significantly higher mortality rate when compared with the rest of the study participants. The adjusted hazard ratio of positive serum CrAg for all-cause mortality was 4.50 (P = 0.028), similar to other African cohorts.16–18 Therefore, serum CrAg positivity, even when detected and treated early to prevent progression to CM, confers a poor prognosis.17–19,48 One limitation of our study is that we did not use the new point-of-care CrAg lateral flow assay (LFA),49 which is more sensitive than latex agglutination and may have diagnosed the participant who screened negative and then developed CM 2 weeks after starting ART. Until more sensitive methods are operationalized, a negative CrAg screening result should not preclude retesting if signs or symptoms of CM develop after ART initiation. The impact of pre-ART CrAg screening using the LFA on post-ART mortality is currently being evaluated in Uganda.

Our pre- and early ART screening also identified a significant number of patients (13%) with subclinical TB infection that likely would not otherwise have been recognized at baseline and demonstrated that the incidence of TB in the first 3 months of ART decreased after effective baseline screening.50 The intensive case finding tool was highly nonspecific; sputum smear analysis had low sensitivity; sputum culture was unreliable because of long sample transport times, slow to process, and too expensive to be a cost-effective screening tool; and individualized clinical assessment required advanced training and was highly provider-dependent. Chest radiographs were not routinely available because of issues surrounding lack of electricity and equipment disrepair, even in a district hospital. More reliable and convenient tests are needed for effective and widespread TB screening as no test was sufficiently sensitive and specific (Table 1; see Figure S1, Supplemental Digital Content, https://links.lww.com/QAI/A626). In addition to Xpert MTB/RIF, which was unavailable in Kiboga during the study period, a promising new TB test is urine lipoarabinomannan LFA (LAM); when combined with sputum smear, LAM LFA can improve overall sensitivity particularly in immunosuppressed HIV-positive populations.32,45,51

The large number of TB cases present at baseline (10.9% of the cohort, of which 72.9% were pulmonary infections) increases the risk of nosocomial transmission to other HIV-infected clinic patients. The level of prevalent TB in this rural population (nearly 11%) was greater than the 6.5% reported in the urban Infectious Diseases Institute cohort in Kampala, Uganda.52 This difference could be explained by decreased access to health care facilities, less diagnostic capacity to diagnose smear-negative and extrapulmonary cases (with low rates of empiric treatment), and lack of integrated HIV/TB care in the rural setting leading to a large pool of undiagnosed cases before our intensified screening intervention. We support the integration of TB and HIV care, which has been shown to improve outcomes53 and is recommended by the WHO.

Extrapulmonary and smear-negative cases comprised a majority (85%) of the TB cases diagnosed after ART initiation and occurred throughout the follow-up period. Overall, 35% of the TB cases were extrapulmonary, much higher than the national proportion in Uganda of 11%,46 perhaps due to modulation of the disease after ART and unrecognized immune reconstitution inflammatory syndrome or unmasked TB.50

Patients with TB at baseline had a significantly higher mortality rate than those without TB. The 16.7% of subjects with TB who died in the first 6.5 months on ART is slightly higher than previously reported data (13.7% at 8 months and 12%–15% at 6 months, respectively)27,36 and suggests that screening did not decrease TB-specific mortality. TB was the single most common cause of death, underlying 23.1% of cohort deaths. Although this percentage closely matches previous meta-analyses of post-ART mortality,3,4 the contribution of CM to cohort mortality was dramatically lower than expected. Although mortality in our cohort at 6 months post-ART initiation was also lower than other sub-Saharan cohorts,6,37,54–60 the average baseline CD4 count was higher, possibly due to late rollout of ART and patients accessing care earlier, high pre-ART mortality, and barriers to care (e.g. transport) for the sickest individuals in Kiboga District.

Our findings agree with previous studies where male sex, anemia, low BMI, and TB infection were independent predictors of death, but differ in that low CD4 count was not an independent predictor of death.3–5,11,58,60,61 Many of the published risk factors for death in HIV patients starting ART come from urban sites early in the ART rollout in SSA. The difference in our risk factor analysis could be attributed to factors unique to rural populations. Anemia, which was strongly predictive of mortality, is a risk factor that is likely impacted by rural behaviors and environments. Late presentation to HIV care due to distance and difficulty accessing clinic services increases the burden of OIs, many of which cause or coincide with anemia; this overlap may explain why anemia dropped out as a risk factor for mortality when serum CrAg was added to the multivariate regression (Table 3). Subsistence farming frequently involves limited access to meat and other densely nutritious foods. Reduced consumption of vitamin B12, iron, and folate could further contribute to low hemoglobin levels.

Five years after the renewal of President's Emergency Plan for AIDS Relief, OIs continue to contribute to significant ART-associated early mortality in SSA. Baseline screening was successful at identifying active TB and asymptomatic cryptococcal antigenemia. Although TB-related mortality did not change, post-ART CM incidence was low in the setting of preemptive fluconazole treatment for serum CrAg-positive subjects. Given the continued burden of TB coinfection and the difficulty of diagnosis, improved rapid point-of-care TB diagnostics will be needed to scale up pre-ART TB screening and improve early ART outcomes.

ACKNOWLEDGMENTS

The authors thank the dedicated members of our study team: Stella Namirembe Magara, Justine Bukirwa, Samuel Kabanda, Abdulatif Agaba, Robert Mutumba, and Grace Menya. They also thank the Kiboga District Hospital Medical superintendents for partnering with the Infectious Diseases Institute to develop Kiboga as a rural research site. They thank Richard Mwesiga of the Infectious Diseases Institute extended Kibaale Kiboga project, and Alex Coutinho, Agnes Kiragga, Allan Etonu, Henry Onen, and Doreen Kizza of the Infectious Diseases Institute for their support.

REFERENCES

1. Global Update on HIV Treatment 2013: Results, Impact and Opportunities. Kuala Lumpur, Malaysia: World Health Organization; 2013.
2. Antiretroviral Medicines in Low- and Middle-Income Countries: Forecasts of Global and Regional Demand for 2013–2016. Geneva, Switzerland, World Health Organization; 2014.
3. Gupta A, Nadkarni G, Yang W-T, et al.. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2011;6:e28691.
4. Lawn SD, Harries AD, Anglaret X, et al.. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897–1908.
5. Castelnuovo B, Manabe Y, Kiragga A, et al.. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis. 2009;49:965–972.
6. Zachariah R, Fitzgerald M, Massaquoi M, et al.. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006;20:2355–2360.
7. Kassa A, Tekab A, Shewaamarec A, et al.. Incidence of tuberculosis and early mortality in a large cohort of HIV infected patients receiving antiretroviral therapy in a tertiary hospital in Addis Ababa, Ethiopia. Trans R Soc Trop Med Hyg. 2012;106:363–370.
8. Tadesse K, Haile F, Hiruy N. Predictors of mortality among patients enrolled on antiretroviral therapy in Aksum hospital, Northern Ethiopia: a retrospective cohort study. PLoS One. 2014;9:e87392.
9. Russell E, Charalambous S, Pemba L, et al.. Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health. 2010;10:433.
10. Moore D, Yiannoutsos C, Musick B, et al.. Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviraltherapy in rural Uganda. J Acquir Immune Defic Syndr. 2011;58:289–296.
11. Toure S, Kouadio B, Seyler C, et al.. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22:873–882.
12. Nash D, Wua Y, Elula B, et al.. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries. AIDS. 2011;25:1523–1533.
13. Lahuerta M, Lima J, Nuwagaba-Biribonwoha H, et al.. Factors associated with late antiretroviral therapy initiation among adults in Mozambique. PLoS One. 2012;7:e37125.
14. Ndawinz J, Chaix B, Koulla-Shiro S, et al.. Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis. J Antimicrob Chemother. 2013;68:1388–1399.
15. IeDea, Collaborations ARTC, Avila D, Althoff KN, et al.. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr. 2014;65:e8–e16.
16. Park B, Wannemuehler K, Marston B, et al.. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525–530.
17. Liechty C, Solberg P, Were W, et al.. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007;12:929–935.
18. Jarvis J, Lawn S, Vogt M, et al.. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48:856–862.
19. Meyer A, Kendi C, Penner J, et al.. The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop Med Int Health. 2013;18:495–503.
20. Ganiem AR, Indrati AR, Wisaksana R, et al.. Asymptomatic cryptococcal antigenemia is associated with mortality among HIV-positive patients in Indonesia. J Int AIDS Soc. 2014;17:18821.
21. Worodria W, Massinga-Loembe M, Mayanja-Kizza H, et al.. Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. Clin Dev Immunol. 2011;2011:758350.
22. Mamoojee Y, Shakoor S, Gorton R, et al.. Short Communication: low seroprevalence of cryptococcal antigenaemia in patients with advanced HIV infection enrolling in an antiretroviral programme in Ghana. Trop Med Int Health. 2011;16:53–56.
23. Oyella J, Meya D, Bajunirwe F, et al.. Prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV-infected adults in Uganda: a cross-sectional study. J Int AIDS Soc. 2012;15:15.
24. Meya D, Manabe Y, Castelnuovo B, et al.. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51:448–455.
25. Osazuwa O, Dirisu O, Okuonghae E. Cryptococcal antigenemia in anti-retroviral naïve AIDS patients: prevalence and its association with CD4 cell count. Acta Med Iran. 2012;50:344–347.
26. Jarvis JN, Harrison TS, Lawn SD, et al.. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One. 2013;8:e69288.
27. Lawn S, Myer L, Bekker L, et al.. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605–1612.
28. Lawn S, Harries A, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010;5:18–26.
29. Wood R, Middelkoop K, Myer L, et al.. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med. 2007;175:87–93.
30. Moore D, Liechty C, Ekwaru P, et al.. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007;21:713–719.
31. Bassett I, Wang B, Chetty S, et al.. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010;51:823–829.
32. Lawn S, Kerkhoff A, Vogt M, et al.. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012;12:201–209.
33. Hanifa Y, Fielding K, Charalambous S, et al.. Tuberculosis among adults starting antiretroviral therapy in South Africa: the need for routine case finding. Int J Tuberc Lung Dis. 2012;16:1252–1259.
34. Lawn S, Brooks S, Kranzer K, et al.. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011;8:e1001067.
35. Lawn SD, Harries AD, Meintjes G, et al.. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2012;26:2121–2133.
36. Nansera D, Bajunirwe F, Elyanu P, et al.. Mortality and loss to follow-up among tuberculosis and HIV co-infected patients in rural southwestern Uganda. Int J Tuberc Lung Dis. 2012;16:1371–1376.
37. Gupta A, Wood R, Kaplan R, et al.. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One. 2013;8:e55824.
38. Granich R, Williams B, Montanerc J. Fifteen million people on antiretroviral treatment by 2015: treatment as prevention. Curr Opin HIV AIDS. 2013;8:41–49.
39. Dube C, Nozaki I, Hayakawa T, et al.. Expansion of antiretroviral treatment to rural health centre level by a mobile service in Mumbwa district, Zambia. Bull World Health Organ. 2010;88:788–791.
40. Mutevedzi PC, Lessells RJ, Heller T, et al.. Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes? Bull World Health Organ. 2010;88:593–600.
41. Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living With HIV in Resource-Constrained Settings. World Health Organization; 2011.
42. The State of Uganda Population Report. UNFPA, Kampala, Uganda; 2008:1–115.
43. 2013 Uganda HIV and AIDS Country Progress Report. Kampala, Uganda: Uganda AIDS Commission; 2014.
44. Boulware DR, Meya DB, Muzoora C, et al.. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370:2487–2498.
45. Nakiyingi L, Moodley VM, Manabe YC, et al.. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr. 2014;66:270–9.
46. Global Tuberculosis Report. Geneva, Switzerland, World Health Organization; 2014.
47. Manual of the National Tuberculosis and Leprosy Programme. Kampala, Uganda, Republic of Uganda Ministry of Health; 2010.
48. Manabe YC, Nonyane BA, Nakiyingi L, et al.. Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda. PLoS One. 2014;9:e101459.
49. Jarvis J, Percival A, Bauman S, et al.. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urinefrom patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53:1019–1023.
50. Manabe Y, Breen R, Perti T, et al.. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis. 2009;199:437–444.
51. Shah M, Ssengooba W, Armstrong D, et al.. Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals with suspected tuberculosis in Uganda. AIDS. 2014;28:1307–14.
52. Hermans S, van Leth F, Manabe Y, et al.. Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study. HIV Med. 2012;13:337–344.
53. Hermans SM, Castelnuovo B, Katabira C, et al.. Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda. J Acquir Immune Defic Syndr. 2012;60:e29–35.
54. Weidle P, Malamba S, Mwebaze R, et al.. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360:34–40.
55. Coetzee D, Hildebrand K, Boulle A, et al.. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887–895.
56. Wester C, Kim S, Bussmann H, et al.. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005;40:336–343.
57. Ferradini L, Jeannin A, Pinoges L, et al.. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335–1342.
58. Etard J, Ndiaye I, Thierry-Mieg M, et al.. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181–1189.
59. Makombe S, Harries A, Yu J, et al.. Outcomes of tuberculosis patients who start antiretroviral therapy under routine programme conditions in Malawi. Int J Tuberc Lung Dis. 2007;11:412–416.
60. Johannessen A, Naman E, Ngowi B, et al.. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52.
61. Stringer J, Zulu I, Levy J, et al.. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782–793.
Keywords:

cryptococcal antigen; cryptococcal meningitis; screening; antiretroviral therapy; early mortality; unmasking tuberculosis; tuberculosis; anemia

Supplemental Digital Content

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.